-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WvZ7Q9xFMJUCkgRKBgoACcRvZ+e+AwJn70MeH9ZJB8nyEUfqkUQleI0/q348YI67 gJuWC+/CXRUkJUuHj4qNxw== 0001193125-07-083305.txt : 20070418 0001193125-07-083305.hdr.sgml : 20070418 20070418060430 ACCESSION NUMBER: 0001193125-07-083305 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20070413 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20070418 DATE AS OF CHANGE: 20070418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 07772238 BUSINESS ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 5105741400 MAIL ADDRESS: STREET 1: 34801 CAMPUS DR CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):

April 13, 2007

 

PDL BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   000-19756   94-3023969

(State or other jurisdiction

of incorporation)

   (Commission File No.)  

(I.R.S. Employer

Identification No.)

34801 Campus Drive

Fremont, California 94555 (Address of principal executive offices)

Registrant’s telephone number, including area code: (510) 574-1400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01. Other Events.

On April 13, 2007, L. Patrick Gage, Ph.D, chairman of the board of PDL BioPharma, delivered a letter to Third Point LLC regarding various matters. A copy of this letter is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits.

 

Exhibit No.

   

Description

99.1    Letter from L. Patrick Gage, Ph.D., chairman of the board of PDL BioPharma, to Third Point LLC, dated April 13, 2007.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 18, 2007

 

PDL BioPharma, Inc.

By:  

/s/ Andrew Guggenhime

  Andrew Guggenhime
  Senior Vice President and
Chief Financial Officer

 

3

EX-99.1 2 dex991.htm LETTER FROM L. PATRICK GAGE, PH.D. Letter from L. Patrick Gage, Ph.D.

Exhibit 99.1

[PDL BioPharma, Inc. letterhead]

VIA FACSIMILE AND OVERNIGHT DELIVERY

April 13, 2007

 

Daniel S. Loeb    Phone: 212-224-7400
Chief Executive Officer    Fax: 212-224-7401
Third Point LLC   
390 Park Avenue   
New York, NY 10022   

Dear Dan:

To follow up, and elaborate further on our conversation yesterday, as I stated, I am available, along with our CEO, Mark McDade, to meet with you in person to discuss your views and specific recommendations regarding PDL. I believe that this meeting would be most constructive and valuable if Mark and I were both present. Following this joint session, I would also be available to meet with you without Mark present to discuss your views regarding PDL management.

We could also contemplate a meeting in conjunction with one of our next board meetings at which the full Board could hear your specific views and suggestions regarding PDL. In this case, I would propose a substantive pre-meeting between you, selected outside directors of PDL, and members of management to discuss your views and recommendations. This meeting would then be followed by a session with the outside directors to discuss your views regarding management.

Dan, Mark and I and other members of the PDL Board are interested in meeting with you and hearing your thoughts and suggestions. I believe, however, that these meetings can only be productive if all participants are willing to conduct these sessions in a constructive and professional manner. To be clear, I am only willing to talk about PDL and its ongoing strategy in meetings that are conducted in a professional manner where all parties are respectful; otherwise constructive dialogue is very challenging.

The Board is unanimous in our support of Mark McDade’s leadership and the management team at PDL, and we are all focused on maximizing long-term stockholder value. We believe the Company’s current strategy will deliver significant stockholder value both in the near-term and the long-term. As I have said, we are open to discuss your views on our strategy and evaluate their merits.

Sincerely,

/s/ L. Patrick Gage

L. Patrick Gage

PDL BioPharma, Inc.

Chairman of the Board

-----END PRIVACY-ENHANCED MESSAGE-----